Table 3.

Characterization of study participants based on serum creatinine measurements during intensive phases of MDR-TB treatment at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia

Intensive phase of treatment (number of subjects on follow-up)	Serum creatinine (mg/dL) (Mean ± SEM) (95% CI)	Mean change of serum creatinine from baseline (%)	N(%) of participants with >50% increase of serum creatinine from baseline
Baseline (n = 808)	0.75 ± 0.02 [0.71–0.78]	–	–
1st month (n = 769)	0.82 ± 0.02 [0.78–0.87]	2.9	83 (10.79)
2nd month (n = 717)	0.85 ± 0.02 [0.81–0.89]	20.67	103 (14.36)
3rd month (n = 661)	0.84 ± 0.01 [0.81–0.88]	13.3	105 (15.88)
4th month (n = 619)	0.86 ± 0.02 [0.81–0.91]	75.6	101 (16.32)
5th month (=582)	0.86 ± 0.02 [0.82–0.91	1.9	90 (15.46)
6th month (n = 533)	0.84 ± 0.01 [0.81–0.88]	−33.4	84 (15.75)
7th month (n = 482)	0.82 ± 0.01 [0.80–0.85]	−47	76 (15.76)
8th month (n = 415)	0.83 + 0.01 [0.81–0.86]	−74.6	75 (18.07)